Black Diamond Therapeutics (BDTX) Equity Ratio (2018 - 2025)
Black Diamond Therapeutics' Equity Ratio history spans 6 years, with the latest figure at 0.78 for Q4 2025.
- For Q4 2025, Equity Ratio rose 15.54% year-over-year to 0.78; the TTM value through Dec 2025 reached 0.78, up 15.54%, while the annual FY2025 figure was 0.78, 15.54% up from the prior year.
- Equity Ratio reached 0.78 in Q4 2025 per BDTX's latest filing, down from 0.8 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.9 in Q1 2021 to a low of 0.68 in Q4 2024.
- Average Equity Ratio over 3 years is 0.78, with a median of 0.8 recorded in 2025.
- Peak YoY movement for Equity Ratio: dropped 15.47% in 2021, then grew 15.54% in 2025.
- A 3-year view of Equity Ratio shows it stood at 0.8 in 2021, then dropped by 14.98% to 0.68 in 2024, then rose by 15.54% to 0.78 in 2025.
- Per Business Quant, the three most recent readings for BDTX's Equity Ratio are 0.78 (Q4 2025), 0.8 (Q3 2025), and 0.8 (Q2 2025).